VINORELBINE TARTRATE

Post-LOE

vinorelbine

ANDAINJECTIONINJECTABLE
Approved
Sep 2012
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT06500494N/ARecruiting

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment

Started Sep 2024
368 enrolled
Advanced Breast Cancer
NCT05583110Phase 2Terminated

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Started Mar 2023
13 enrolled
HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
NCT04299113Phase 1Active Not Recruiting

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

Started May 2020
NCT03801304Phase 2Completed

Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer

Started Jan 2019
80 enrolled
NCT03811418Phase 3Withdrawn

A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Started Jan 2019
0
Advanced Breast CancerHER2-positive Breast Cancer